Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pickering syndrome: acute heart failure with an unexpected actor].

Hipertension y riesgo vascular·2021
Same author

Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers.

Transplantation proceedings·2016
Same author

Safety and efficacy of induction treatment with low thymoglobulin doses in kidney transplantation from expanded-criteria donors.

Transplantation proceedings·2015
Same author

[Measurement of continuous improvement in the safety of oncologic patients].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2013
Same author

Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation.

Transplantation proceedings·2012
Same author

[Exposure to cytotoxic drugs among health care professionals].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2012

Related Experiment Video

Updated: Jun 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Genetic polymorphisms and individualized tacrolimus dosing.

M A López-Montenegro Soria1, J Kanter Berga, S Beltrán Catalán

  • 1Department of Pharmacy, Dr Peset Universitary Hospital, and University of Valencia, Valencia, Spain. lopez-montenegro_ang@gva.es

Transplantation Proceedings
|October 26, 2010
PubMed
Summary
This summary is machine-generated.

Genetic variations in CYP3A5 and MDR1 genes significantly impact tacrolimus levels in renal transplant patients. Understanding these single nucleotide polymorphisms (SNPs) can help personalize tacrolimus dosing for better outcomes.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Related Experiment Videos

Last Updated: Jun 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Area of Science:

  • Pharmacogenomics
  • Transplantation Medicine
  • Drug Metabolism

Background:

  • Pharmacokinetic variability of immunosuppressants like tacrolimus is a challenge in renal transplantation.
  • Genetic polymorphisms in drug-metabolizing enzymes and transporters influence drug response.
  • Individualizing tacrolimus doses is crucial for efficacy and safety post-transplant.

Purpose of the Study:

  • To determine the frequency of specific genetic polymorphisms in renal transplant recipients.
  • To evaluate the impact of these polymorphisms on tacrolimus pharmacokinetics.
  • To assess the potential for personalized tacrolimus dosing based on genetic profiles.

Main Methods:

  • Observational study of 35 renal transplant recipients on tacrolimus-based immunosuppression.
  • Measurement of tacrolimus blood concentrations over the first 6 weeks post-transplant.
  • Analysis of single nucleotide polymorphisms (SNPs) in CYP3A5, MDR1, and PXR genes.

Main Results:

  • Significant differences in tacrolimus concentration/dose ratios were observed based on CYP3A5*3 genotype.
  • Patients with wild-type MDR1 (3435 C/C) genotype had lower tacrolimus concentration/dose ratios.
  • SNP distribution analysis revealed specific frequencies for CYP3A5, MDR1, and PXR polymorphisms in the study cohort.

Conclusions:

  • Single nucleotide polymorphisms in CYP3A5 and MDR1 genes significantly affect tacrolimus absorption and metabolism.
  • These genetic factors represent a valuable tool for optimizing tacrolimus dosage in renal transplant recipients.
  • Pharmacogenetic analysis can guide personalized immunosuppressive therapy after kidney transplantation.